ArticleOncotarget2015
Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Joining up the scattered anticancer knowledge on auraptene and umbelliprenin: a meta-analysis.Scientific reports · 2024Pooled it
- 7-Geranyloxycoumarin modulated metastatic potential of osteosarcoma cells via interaction with MMPs and JAK1/2.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Niosome-encapsulated auraptene reduced the mRNA expression ofInternational journal of ophthalmology · 2024Article
- Protection of Mitochondrial Potential and Activity by Oxyprenylated Phenylpropanoids.Antioxidants (Basel, Switzerland) · 2023Article
- Review
- Doxycycline sensitizes renal cell carcinoma to chemotherapy by preferentially inhibiting mitochondrial translation.The Journal of international medical research · 2021Article
- The Heterogeneity Metabolism of Renal Cell Carcinomas.Advances in experimental medicine and biology · 2021Article
- Coumarins and Gastrointestinal Cancer: A New Therapeutic Option?Frontiers in oncology · 2021Review
- A Review of Auraptene as an Anticancer Agent.Frontiers in pharmacology · 2021Review
- Tumor promoting effects of circRNA_001287 on renal cell carcinoma through miR-144-targeted CEP55.Journal of experimental & clinical cancer research : CR · 2020Article
- Novel nano-vehicle for delivery and efficiency of anticancer auraptene against colon cancer cells.Scientific reports · 2020Article
- Expression of HIF‑1α in cycling stretch‑induced osteogenic differentiation of bone mesenchymal stem cells.Molecular medicine reports · 2019Article
- Auraptene Mitigates Parkinson's Disease-Like Behavior by Protecting Inhibition of Mitochondrial Respiration and Scavenging Reactive Oxygen Species.International journal of molecular sciences · 2019Article
- Type 3 inositol 1,4,5-trisphosphate receptor has antiapoptotic and proliferative role in cancer cells.Cell death & disease · 2019Article
- MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance.Oxidative medicine and cellular longevity · 2019Review
- Crosstalk of protein kinase C ε with Smad2/3 promotes tumor cell proliferation in prostate cancer cells by enhancing aerobic glycolysis.Cellular and molecular life sciences : CMLS · 2018Article
- Early missed abortion is associated with villous angiogenesis via the HIF-1α/VEGF signaling pathway.Archives of gynecology and obstetrics · 2018Article
- Auraptene Attenuates Malignant Properties of Esophageal Stem-Like Cancer Cells.Technology in cancer research & treatment · 2017Article
- The Metabolism of Renal Cell Carcinomas and Liver Cancer.Advances in experimental medicine and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) progression resulting from the uncontrolled migration and enhanced angiogenesis is an obstacle to effective therapeutic intervention. Tumor metabolism has distinctive feature called Warburg effect, which enhances the aerobic glycolysis rapidly supplying the energy for migration of tumor. To manipulate this metabolic change characteristic of aggressive tumors, we utilized the citrus extract, auraptene, known as a mitochondrial inhibitor, testing its anticancer effects against the RCC4 cell line. We found that auraptene impaired RCC4 cell motility through reduction of mitochondrial respiration and glycolytic pathway-related genes. It also strongly disrupted VEGF-induced angiogenesis in vitro and in vivo. Hypoxia-inducible factor 1a (HIF-1a), a key regulator of cancer metabolism, migration and angiogenesis that is stably expressed in RCCs by virtue of a genetic mutation in the von Hippel-Lindau (VHL) tumor-suppressor protein, was impeded by auraptene, which blocked HIF-1a translation initiation without causing cytotoxicity. We suggest that blockade HIF-1a and reforming energy metabolism with auraptene is an effective approach for suspension RCC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.